Emergency Department Use of Intravenous Procainamide for Patients with Acute Atrial Fibrillation or Flutter

Academic Emergency Medicine

Volumn 14, Issue 12, 2007, Pages 1158-1164

  Stiell, Ian G ^a   Clement, Catherine M ^a   Symington, Cheryl ^a   Perry, Jeffrey J ^a   Vaillancourt, Christian ^a   Wells, George A ^a  

^a Department of Epidemiology and Community Medicine (GAW)   (Canada)

Author keywords

atrial fibrillation; procainamide

Indexed keywords

PROCAINAMIDE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVERSION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE TACHYCARDIA; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; SINUS RHYTHM; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; ELECTRIC COUNTERSHOCK; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROCAINAMIDE; RETROSPECTIVE STUDIES;

EID: 36248999354     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1197/j.aem.2007.07.016     Document Type: Article

References (35)

1. Connors S., and Dorian P. Management of supraventricular tachycardia in the emergency department. Can J Cardiol 13 Suppl A (1997) 19A-24A
2. Skanes A.C., and Dorian P. 2004 Canadian Cardiovascular Society Consensus Conference: atrial fibrillation-etiology and initial investigation of atrial fibrillation. Can J Cardiol 21 Suppl B (2005) 11B-14B
3. Michael J.A., Stiell I.G., Agarwal S., and Mandavia D.P. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med 33 (1999) 379-387
4. Wyse D.G., and Simpson C.S. 2004 Canadian Cardiovascular Society Consensus Conference: atrial fibrillation-rate control versus rhythm control-decision making. Can J Cardiol 21 Suppl B (2005) 15B-18B
5. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 48 (2006) 149-246
6. Page R.L. Newly diagnosed atrial fibrillation. N Engl J Med 351 (2004) 2408-2416
7. Taylor D.M., Aggarwall A., Carter M., Garewal D., and Hunt D. Management of new onset atrial fibrillation in previously well patients less than 60 years of age. Emerg Med Aust 17 (2005) 4-10
8. Raghavan A.V., Decker W.W., and Meloy T.D. Management of atrial fibrillation in the emergency department. Emerg Med Clin North Am 23 (2005) 1127-1139
9. Burton J.H., Vinson D.R., Drummond K., Strout T.D., Thode H.C., and McInturff J.J. Electrical cardioversion of emergency department patients with atrial fibrillation. Ann Emerg Med 44 (2004) 20-30
10. Wyse D.G., Waldo A.L., DiMarco J.P., et al., Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
11. Heilbron B., Klein G.J., Talajic M., and Guerra P.G. 2004 Canadian Cardiovascular Society Consensus Conference: atrial fibrillation-management of atrial fibrillation in the emergency department and following acute myocardial infarction. Can J Cardiol 21 Suppl B (2005) 61B-66B
12. Madrid A.H., Moro C., Marin-Huerta E., Mestre L., Novo L., and Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 14 (1993) 1127-1131
13. Halpern S.W., Ellrodt G., Singh B.N., and Mandel W.J. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm-relation to left atrial size. Br Heart J 44 (1980) 589-595
14. Fenster P.E., Comess K.A., Marsh R., Katzenberg C., and Hager W.D. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 106 (1983) 501-504
15. Volgman A.S., Carberry P.A., Stambler B., et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 31 (1998) 1414-1419
16. Stambler B.S., Wood M.A., and Ellenbogen K.A. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation. Circulation 96 (1997) 4298-4306
17. American Heart Association. ACLS Guidelines: part 7.3: management of symptomatic bradycardia and tachycardia. Circulation 112 (2005) IV-67-IV-77
18. Nichol G., McAlister F.A., Pham B., et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 87 (2002) 535-543
19. Borgeat A., Goy J.J., Maendly R., Kaufmann U., Grbic M., and Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 58 (1986) 496-498
20. Suttorp M.J., Kingma J.H., Lie-A-Huen A.H., and Mast E.G. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 63 (1989) 693-696
21. Suttorp M.J., Kingma J.H., Jessurun E.R., et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 16 (1990) 1722-1727
22. Mountantonakis S.E., Moutzouris D.A., Tiu R.V., Papaioannou G.N., and McPherson C.A. Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter. Am J Emerg Med 24 (2006) 407-412
23. Viktorsdottir O., Henriksdottir A., and Arna D.O. Ibutilide for treatment of atrial fibrillation in the emergency department. Emerg Med J 23 (2006) 133-134
24. Stambler B.S., Wood M.A., Ellenbogen K.A., Perry K.T., Wakefield L.K., and Vanderlugt J.T. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 94 (1996) 1613-1621
25. Guo G.B., Ellenbogen K.A., Wood M.A., and Stambler B.S. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol 27 (1996) 1083-1089
26. Vos M.A., Golitsyn S.R., Stangl K., et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 79 (1998) 568-575
27. Ellenbogen K.A., Stambler B.S., Wood M.A., et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28 (1996) 130-136
28. Alboni P., Botto G.L., Baldi N., et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 351 (2004) 2384-2391
29. Martinez-Marcos F.J., Garcia-Garmendia J.L., Ortega-Carpio A., Fernandez-Gomez J.M., Santos J.M., and Camacho C. Comparison of intravenous flecainide, propafenone and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 86 (2000) 950-953
30. Tijunelis M.A., and Herbert M.E. Myth: intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department. Can J Emerg Med 7 (2005) 262-265
31. Hilleman D.E., and Spinler S.A. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy 22 (2002) 66-74
32. Chevalier P., Durand-Dubief A., Burri H., Cucherat M., Kirkorian G., and Touboul P. Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 41 (2003) 255-262
33. Letelier L.M., Udol K., Ena J., Weaver B., and Guyatt G.H. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 163 (2003) 777-785
34. Miller M.R., McNamara R.L., Segal J.B., et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract 49 (2000) 1033-1046
35. Roy D., Rowe B.H., Stiell I.G., et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 44 (2004) 2355-2361